Production (Stage)
Nexien BioPharma, Inc.
NXEN
$0.0145
$0.00552.63%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -10.06% | 79.10% | -74.68% | -2.43% | -77.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.06% | 79.10% | -74.68% | -2.43% | -77.09% |
| Operating Income | 10.06% | -79.10% | 74.68% | 2.43% | 77.09% |
| Income Before Tax | 43.42% | -61.22% | 57.28% | 7.59% | 33.42% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 43.42% | -61.22% | 57.28% | 7.59% | 33.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 43.42% | -61.22% | 57.28% | 7.59% | 33.42% |
| EBIT | 10.06% | -79.10% | 74.68% | 2.43% | 77.09% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 50.00% | -50.00% | 58.33% | 13.33% | 38.46% |
| Normalized Basic EPS | 40.00% | -50.00% | 57.14% | 11.11% | 37.50% |
| EPS Diluted | 50.00% | -50.00% | 58.33% | 13.33% | 38.46% |
| Normalized Diluted EPS | 40.00% | -50.00% | 57.14% | 11.11% | 37.50% |
| Average Basic Shares Outstanding | 6.61% | 8.69% | 9.13% | 7.83% | 5.98% |
| Average Diluted Shares Outstanding | 6.61% | 8.69% | 9.13% | 7.83% | 5.98% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |